December 16, 2016 08:21 AM EST
Pharma

In a first, As­traZeneca gains rights to an an­ti­sense KRAS drug in $165M Io­n­is deal

Arsalan Arif

Founder

As­traZeneca is hand­ing over $28 mil­lion to Io­n­is in ex­change for rights to de­vel­op one of its ear­ly-stage can­cer drugs. The phar­ma gi­ant has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk’s Ca­griSe­ma shows 15.7% weight loss in sec­ond piv­otal tri­al

Beam shares promis­ing first clin­i­cal da­ta on gene edit­ing treat­ment for a lung and liv­er dis­ease 

How blue­bird's buy­out of­fer went from $100M up­front to $29M

Sun Phar­ma to ac­quire Check­point Ther­a­peu­tics and its an­ti-PD-L1 an­ti­body

Ex­clu­sive: Dai­ichi Sankyo, John­son & John­son part­ner with RNA de­liv­ery start­up No­sis Bio

sponsored

Obe­si­ty drug de­vel­op­ment—still room to grow

A service from the Financial Times